← All trials
NCT05457257
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2022
- Primary completion
- Dec 29, 2023
- Completion date
- Feb 28, 2025
- First posted
- Jul 13, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Foundation MedicineCollaborator
- MerckCollaborator
- Myrexis Inc.Collaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.